Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà
MedNavigator.ru - Ïîèñê è ïîäáîð ëå÷åíèÿ â Ðîññèè è çà ðóáåæîì

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Ôîðóìû âðà÷åáíûõ êîíñóëüòàöèé > Àêóøåðñòâî è ãèíåêîëîãèÿ > Ôîðóì äëÿ îáùåíèÿ âðà÷åé àêóøåðîâ-ãèíåêîëîãîâ

Ôîðóì äëÿ îáùåíèÿ âðà÷åé àêóøåðîâ-ãèíåêîëîãîâ Ôîðóì ïðåäíàçíà÷åí äëÿ îáùåíèÿ ìåæäó âðà÷àìè àêóøåðàìè-ãèíåêîëîãàìè.

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #1  
Ñòàðûé 25.05.2003, 14:04
Max Melker Max Melker âíå ôîðóìà Ïîë ìóæñêîé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 19.05.2003
Ñîîáùåíèé: 65
Max Melker ýòîò ó÷àñòíèê èìååò ïëîõóþ ðåïóòàöèþ íà ôîðóìå
Question Ïîáîðåìñÿ ñ ãåñòîçîì

Óâàæàåìûå êîëëåãè!Íåñêîëüêî ïîäóñòàâ îò ïî÷òè áåçðåçóëüòàòíîé áîðüáû ñ ãåñòîçàìè,ñ óñïåõîì ïðèìåíèë íåêîòîòîðûå ïðèíöèïû èç "Îñíîâû êëèíè÷åñêîé ãèäðîñòàçèîëîãèè"...Õîòåë áû îáñóäèòü ñî ñòàðøèìè êîëëåãàìè,èìåþùèìè òå æå ïðîáëåìû,à òî â íàøåì ÃÐÄ äîêòîðà óæ î÷åíü îðòîäîêñàëüíûå,ïî ðóêàì áüþò
Îòâåòèòü ñ öèòèðîâàíèåì
  #2  
Ñòàðûé 07.08.2003, 16:59
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,313
Ïîáëàãîäàðèëè 33,197 ðàç(à) çà 31,547 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìûé Ìàêñ!
Íå ìîãëè áû Âû ÿñíåå èçëîæèòü ñóòü Âàøèõ ïîäõîäîâ ê âåäåíèþ ãåñòîçîâ èëè ïðè óãðîçå ïðåðûâàíèÿ áåðåìåííîñòè.
 ñâîþ î÷åðåäü ïðåäñòàâëÿþ Âàì ññûëêè, êîòîðûå Âàñ ìîãóò çàèíòåðåñîâàòü:
Acta Obstet Gynecol Scand. 2001 Aug;80(8):753-6.

Antibiotic treatment for threatened abortion during the early first trimester in women with previous spontaneous abortion.

Ou MC, Pang CC, Chen FM, Su CH, Ou D.

Department of Obstetrics and Gynecology, Su Woman Hospital, Taipei 108, Taiwan.

BACKGROUND: We retrospectively examined the usefulness of antibiotic therapy for management of first-trimester threatened abortion in women with previous spontaneous abortion. METHODS: From 1993 through 1999, women with first-trimester threatened abortion received antibiotic therapy. Only those with gestational age less than 9 weeks and previous spontaneous abortion were included in this analysis. Women with mild abdominal cramping received amoxicillin plus erythromycin for 1 week; those with severe abdominal pain received amoxicillin plus clindamycin for 1 week. Recurrence was documented on the basis of either lower abdominal pain or vaginal bleeding. RESULTS: Of the 23 women included, 15 (65%) had abnormal vaginal flora (a score above 4, Nugent's criteria). Seven of 16 women who received amoxicillin plus clindamycin and three of seven who received amoxicillin plus erythromycin had complete resolution of lower abdominal pain and vaginal bleeding without recurrence (p=1). The recurrence rate was higher, though not significantly, in women with abnormal bacterial vaginal flora (8/15 vs. 2/8, p=0.379). Twenty-two (96%) of the 23 pregnancies were carried to term, with no identifiable neonatal anomalies. CONCLUSIONS: These results suggest the usefulness of early antibiotic therapy in preventing pregnancy loss in women with threatened abortion early in the first trimester, and warrant further clinical trials.

European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 95, Issue 2 , April 2001, Pages 218-221


Non-pregnant circulatory volume status predicts subsequent pregnancy outcome in normotensive thrombophilic formerly preeclamptic women.

M. E. A. Spaanderman, , a, R. Aardenburga, T. H. A. Ekharta, H. W. F. van Eyndhovena, O. W. H. van der Heijdena, J. van Eycka, P. W. de Leeuwb and L. L. H. Peetersa

a Academic Hospital Maastricht and Sophia Hospital Zwolle, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands
b Departments of Obstetrics & Gynecology and Internal Medicine, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands

Abstract
Background: Preeclampsia seems to be superimposed upon a preexisting hemodynamic, hemostatic, autoimmune or metabolic disorder. We tested the hypothesis that in normotensive thrombophilic formerly preeclamptic subjects, the non-pregnant circulatory volume status predicts the development of subsequent hypertensive pregnancy and/or fetal growth restriction.

Methods: In 250 non-diabetic formerly preeclamptic women and 15 normal parous controls, we measured and calculated the following variables at least 5 months postpartum at day 5 (±2) of the menstrual cycle: mean arterial pressure, body mass index, plasma volume and the clotting function. In the subsequent pregnancy we determined, birth weight, birth-weight centile and the incidence of preterm birth, fetal growth restriction, pregnancy-induced hypertension, preeclampsia and HELLP-syndrome. We only included in the final analysis normotensive subjects with a thrombophilic phenotype at the time of the pre-pregnant screening, who had a subsequent singleton pregnancy, ongoing beyond 16 weeks gestation within 1 year after pre-pregnant evaluation. As a consequence, 23 formerly preeclamptic women and 12 controls were eligible for final analysis. The thrombophilic formerly preeclamptic participants received aspirin in combination with low-molecular-weight heparin throughout pregnancy. If thrombophilia was diagnosed on the basis of hyperhomocysteinemia, the treatment consisted of aspirin, pyridoxine and folic acid, instead.

Results: Among 250 formerly preeclamptic 131/250 (52%) had a normotensive thrombophilic phenotype. Only 23 (18%) of these 131 participants had an ongoing pregnancy within 1 year. They were allocated to subgroup THROMB. None of the controls had hypertension or thrombophilia. In contrast, 12/15 (80%) controls had an ongoing pregnancy within a year. The observations in the THROMB subgroup were compared with those in the control group. None of the baseline demographic and bloodpressure variables differed between THROMB and controls. With respect to pregnancy outcome, the incidence of the following pregnancy complications were observed in THROMB subjects: preterm birth: 9%, pregnancy-induced hypertension: 44%, preeclampsia: 13%, HELLP-syndrome: 13%, and fetal growth restriction: 30%. A low non-pregnant plasma volume was found to predispose for hypertensive complications in a subsequent pregnancy.

Conclusion: Pre-pregnant plasma volume in normotensive thrombophilic formerly preeclamptic women have predictive value with respect to hypertensive complications in the subsequent pregnancy.
Îòâåòèòü ñ öèòèðîâàíèåì
  #3  
Ñòàðûé 11.08.2003, 13:24
Max Melker Max Melker âíå ôîðóìà Ïîë ìóæñêîé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 19.05.2003
Ñîîáùåíèé: 65
Max Melker ýòîò ó÷àñòíèê èìååò ïëîõóþ ðåïóòàöèþ íà ôîðóìå
Çäðàâñòâóéòå,dr.Vad!Ðàä,÷òî âû îòêëèêíóëèñü.Ê ñîæàëåíèþ(è ê ñòûäó) ÿ íå âëàäåþ àíãëèéñêèì â äîñòàòî÷íîé ìåðå è íå ìîãó îöåíèòü ïðåäîñòàâëåííóþ Âàìè èíôîðìàöèþ À êîíêðåòíî ÿ õîòåë áû îáñóäèòü ïðèìåíåíèå ÌÀÍÍÍÈÒÎËà 15% ñ öåëüþ êóïèðîâàíèÿ îòåêà ìîçãà ïðè ãåñòîçå.Íàáëþäåíèå:Áîëüíàÿ Ç.,42 ãîäà,ïîñòóïèëà â ðîääîì ñ æàëîáàìè íà ãîëîâíóþ áîëü,ìåëüêàíèå "ìóøåê" â ïîëå çðåíèÿ,îäûøêó ïðè ïîäú¸ìå ïî ëåñòíèöå. Óêàçàííûå æàëîáû â òå÷åíèè 7-8 äíåé.Îáúåêòèâíî îò¸êè íà ãîëåíÿõ âûðàæåííûå,íà ïåð áð. ñòåíêå,êèñòÿõ ðóê óìåðåííûå,ïàñòîçíîñòü ëèöà.ÀÄ 150/100,140/100 ìì.ðò.ñò.Àí. ìî÷è: áåëîê 1,65 ã/ë,ëåéêîöèòû 7-6-8 â ï.çð.Àí êðîâè:Hb 88 ã/ë,Ht 25%,L 5,6*10(9),Er 2,7*10(12),Tr 180*10(9)....Äèàãíîç:Áåðåìåííîñòü 33-34 íåäåëè.Ïðåýêëàìïñèÿ. Îò ïðåäëîæåííîãî ïðåðûâàíèÿ áåðåìåííîñòè áîëüíàÿ êàòåãîðè÷åñêè îòêàçàëàñü ïî ðåëèãèîçíûì ïðè÷èíàì ââèäó âîçìîæíîé ãèáåëè ðåá¸íêà.Áûëà ïðîâåäåíà ñåäàòèâíàÿ,ìàãíåçèàëüíàÿ òåðàïèÿ,ñîçäàí ËÎÐ. Ïðîâåäåíà èíôóçèÿ ìàííèòîëà 15% èç ðàñ÷¸òà 1 ã. ñóõîãî âåùåñòâà íà 1 êã âåñà áîëüíîé.Ñ öåëüþ ïðåäîòâðàùåíèÿ ðèêîøåòà ïà äåñÿòîé ìèíóòå èíôóçèè ââåäåíî ëàçèêñ 2 ìã. â/â .Êîëè÷åñòâî âûäåëåííîé ìî÷è ñîñòàâèëî 3,1 (!) ëèòðà çà 3 ÷àñà,ÀÄ ñòàáèëèçèðîâàëîñü íà óðîâíå 120/80,130/90 ìì.ðò.ñò.,íåâððîëîãè÷åñêàÿ ñèïòîìàòèêà êóïèðîâàëàñü.Ïðèçíàêîâ îïàñíîé ãèïîâîëåìèè íåò.Àí. ìî÷è cito:áåëîê 0,66 ã/ë(!).Äàëüíåéøåå ëå÷åíèå ïðîâîäèëîñü ñ ó÷¸òîì ïðèíöèïîâ,èçëîëæåííûõ â "Îñíîâû êëèíè÷åñêîé ãèäðîñòàçèîëîãèè" è ïîçâîëèëî ïðîëîíãèðîâàòü áåðåìåííîñòü â òå÷åíèè 2-õ íåäåëü.Õîðîøî,íî ñòðàøíîâàòî,âîò è çàõîòåëîñü îáñóäèòü.Êàòàìíåç,êñòàòè,õîðîøèèé:Êåñàðåâî ñå÷åíèå â ñðîêå 36 íåäåëü,ìàëü÷èê 2800ã,âûïèñàëè îáîèõ íà 5-å ñóòêè
P.S. Êíèãà çäåñü:[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Êîììåíòàðèè ê ñîîáùåíèþ:
TataStar îäîáðèë(à):
Îòâåòèòü ñ öèòèðîâàíèåì
  #4  
Ñòàðûé 11.08.2003, 14:57
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,313
Ïîáëàãîäàðèëè 33,197 ðàç(à) çà 31,547 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìûé Ìàêñ!
Ê ñîæàëåíèþ, íå óäàñòñÿ Âàñ ïîëíî îçíàêîìèòü ñî âñåìè ìîìåíòàìè çàðóá. îïûòà ïî Âàøåé òåìàòèêå.
 ïåðâîé ñòàòüå ãîâîðèòñÿ î ïðèìåíåíèè àíòèáèîòèêîâ (amoxicillin plus clindamycin èëè amoxicillin plus erythromycin) äëÿ ëå÷åíèÿ óãðîçû âûêèäûøà â ïåðâîì òðèìåñòðå (êàê-òî Âû ïèñàëè íà äð. ôîðóìå î ïðèìåíåíèè ÀÁ);
âî âòîðîé- î âàæíîñòè îïðåäåëåíèÿ îáüåìà ïëàçìû ó æåíùèí äî áåðåììåííîñòè (ñ ãåñòîçîì â àíàìíåçå), ÷òî ìîæåò ïðåäñêàçàòü ðàçâèòèå ãåñòîçà ïðè ïîñëåäóþùåé áåðåìåííîñòè.
Âàæíîñòü îáüåìà ïëàçìû â ãåíåçå ãèïåðòåíçèè áåðåìåííûõ óêàçûâàþ è äðóãèå èññëåäîâàòåëè:
J Hypertens. 1992 Jan;10(1):61-8.
Extracellular fluid volumes in pregnancy-induced hypertension.
Brown MA, Zammit VC, Mitar DM.
Department of Renal Medicine, St George Hospital, Sydney, Australia.
Ó íîðì. áåðåìåííûõ óâåë. îáüåì ïëàçìû, ýêñòðàêëåò. îáù. îáüåì æèäêîñòè è èõ ñîîòíîøåíèå óâåëè÷èâàåòñÿ, ïðè ãèïåðòåíçèè ÎÏ/ÝÎÎÆ ïîíèæàåòñÿ çà ñ÷åò óìåíüøåíèÿ îáüåìà ïëàçìû. Õîòÿ èìååòñÿ êîððåëÿöèÿ ìåæäó ãåìàòîêðèòîì è ÎÏ, îí ÿâëÿåòñÿ ñëàáûì ïðåäèêòîðîì ñíèæ.îáüåìà ïëàçìû Äèàñòîë. ÀÄ ñâûøå 100 mmHg, ïðîòåèíóðèÿ è è âûñîêèå öèôðû ãèïåðòåíçèè òîëüêî ÿâèëèñü íàèáîëåå ÷óâñòâèò. ìàðêåðàìè ñíèæ. îáüåìà ïëàçìû.

Òàêæå èçó÷àëîñü ââåäåíèå îñìî-îíêîàêòèâí. ðàñòâîðîâ ïðè ãèïåðòîíèè áåðåìåííûõ:
Int J Biol Res Pregnancy. 1982;3(2):77-80.
Hemodynamic, adjusted treatment of hypertension in pregnancy. - Part I: Infusionary osmo-oncotherapy.
Schwarz R, Retzke U.

..intravenous infusions of 10% mannitol, 40% sorbitol, 10% low molecular dextran, 10% low molecular dextran with 10% mannitol, as well as of the successive application of 40% sorbitol and 10% low molecular dextran in hypertensive late pregnant patients...

Àâòîðû îòìå÷àþò, ÷òî â òÿæåëûõ ñëó÷àÿõ osmo-oncotherapy íàèáîëåå ïðåèìóùåñòâåííà, òê ïîâûøàåò ñåðäå÷íûé âûáðîñ, ñíèæ. îáù. ïåðèô. ñîïðîòèâëåíèå, ìîáèëèçèðóåò îòå÷íóþ æèäêîñòü è ïîâûøàåò äèóðåç.

Anaesthesist. 1980 May;29(5):282-8. Intensive care of severe preeclampsia-eclampsia. A report on 22 cases. Larsen R, Turner E, Radke J.

Ëå÷åíèå îòåêà ìîçãà: controlled hyperventilation, steroids and mannitol. Äèàñòîë. ÀÄ ñâûøå 100 ìì ðò.ñò. ñíèæàëîñü hydralazine. Äèóðåç êîíòðîëèðîâàëñÿ óâåëè÷åíèåì ãèïîâîëåìèè ââåäåíèåì albumin è plasma expanders.

 öåëîì, âåäåíèå ãåñòîçîâ íà óðîâåíü 70-õ âêðàòöå çäåñü: áåç ïåðåâîäà

Br J Anaesth. 1977 Jan;49(1):3-9. The management of severe pre-eclampsia and eclampsia.

Hibbard BM, Rosen M.

With improving standards of antenatal care, severe pre-eclampsia dn eclampsia are becoming less common and experience in the management of these conditions is lessening. Co-ordinated plans for the care of patients should be established by obstetricians and anaesthetists working as a team. A suitable regime for drug therapy in severe pre-eclampsia or eclampsia is the following: Initial management Diazepam 10 mg slowly i.v. Pethidine 100-150 mg i.m. or i.v. in incremental dosage, or extradural blocks, if analgesia is also required. Hydrallazine 20 mg i.v. initially, followed by 5 mg at intervals of 20 min until the diastolic pressure is less than 110 mm Hg. Then, preferably by syringe pump in a concentration of 2 mg/ml, at a rate of 2-20 mg/h. If vomiting occurs this can be controlled by administration of atropine. Subsequent management Sedation and anticonvulsant therapy. Continue diazepam and, in severe cases, institute chlormethiazole infusion. Continue analgesia with pethidine or extradural block. Control of hypertension by adjusting the dose of hydrallazine. If tachycardia exceeds 120 beat/min give propanolol 2-4 mg i.v. Plasma protein depletion with groww oedema is treated by administration of salt-free albumin or plasma protein fraction. Diuretic therapy is indicated if there is gross oedema or signs suggestive of acute renal failure. Oliguria associated with increased blood urea may be a result of renal failure or dehydration. The latter should be evident from the patient's condition and central venous pressure, but i.v. fluids and frusemide 20-40 mg can be used as a therapeutic test. Mannitol reduces cerebral oedema and may be given if diuresis has been first produced with frusemide. Potassium chloride is given if the plasma potassium decreases to less than 3 mmol/litre. Heparin therapy is considered if there is clinical evidence of disseminated intravascular coagulation.


Acta Anaesthesiol Scand Suppl. 1975;57:71-8.
Treatment of pre-eclampsia and eclampsia as a hypoperfusion syndrome.

Soder G, Grenroth C, Noree LO, Wiklund PE.

A therapeutical program in pre-eclampsia and eclampsia is presented. The results in 10 patients suggest that the same basic program as is used in the hypoperfusion syndrome can be used in pre-eclampsia and eclampsia: Chlorpromazin to combat vasoconstriction and dilate the vascular bed. Plasma expanders, plasma, albumin and glucose with electrolytes to fill up the dilated vascular bed and restore the tissue perfusion. Buffers to combat acidosis, oxygen to combat hypoxemia, hypertonic Mannitol to mobilize edema. Furosemide to force diuresis.

Òàê, ÷òî ïåðåâîäèòå è ïðèìåíÿéòå: íîâîå - õîðîøî çàáûòîå ñòàðîå.
Ãëàçà áîÿòñÿ, à ðóêè äåëàþò...
Îòâåòèòü ñ öèòèðîâàíèåì
  #5  
Ñòàðûé 13.08.2003, 21:07
Max Melker Max Melker âíå ôîðóìà Ïîë ìóæñêîé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 19.05.2003
Ñîîáùåíèé: 65
Max Melker ýòîò ó÷àñòíèê èìååò ïëîõóþ ðåïóòàöèþ íà ôîðóìå
Çäðàâñòâóéòå,Dr.Vad!Âèäèìî,ïðèäåòñÿ ìíå àíãëèéñêèé ó÷èòüÀ îòíîñèòåëüíî àíòèáàêòåðèàëüíîé òåðàïèè ïðè óãðîçå âûêèäûøà-åñëè àìîêñèöèëëèí åù¸ êàê-òî ìîæíî îïðàâäàòü(õîòÿ ÿ ëè÷íî íå âèæó åãî ïðåèìóùåñòâ ïåðåä ýðèòðîìèöèíîì),òî êëèíäàìèöèí-îòêðîâåííî öèòîòîêñè÷íûé ïðåïàðàò(ýìáðèîí æàëêî).Ïðàêòè÷åñêè æå âî âñåõ ñëó÷àÿõ îòëè÷íî ðàáîòàåò ýðèòðîìèöèí 0,5ã 4ð/ñóò ïåðîðàëüíî(ìíîãî,êîíå÷íî,íî ìåíüøàÿ äîçà ÷àñòî íåýôôåêòèâíà)Õî÷ó,ïðàâäà,çàìåòèòü,÷òî ýòî-êðàéíÿÿ ìåðà,è äëÿ íà÷àëà ÿ ïðîáóþ ñëåäóþùèé êîìïëåêñ ìåð: 1. Âûñîêîáåëêîâàÿ äèåòà,ïîääåðæàííàÿ ôåðìåíòàìè(ôåñòàë,ìåçèì...) 2.ÈÒÒ â îáü¸ìå íå ìåíåå 1-1,5 ë â ñóòêè,âêëþ÷àÿ ãëþêîçó 5%+âèò Ñ 5% 20 ìë,èíôåçîë(åñòåñòâåííî,àìèíîêèñëîòû-òîëüêî ïðè îòñóòñòâèè òîêñèêîçà),10 ìë 25% ìàãíåçèè íà 5% ãëþêîçå(à 0.9% íàòðèé-ïåðñîíà íîí ãðàòà,áåðåìåííûå åãî è òàê ñâåðõ ìåðû ïîòðåáëÿþò)3.Ïîääåðæèâàåì àíàáîëèçì-êàëèÿ îðîòàò 1 ã 4 ð/ñóò ïåðîðàëüíî.4.Âèòàìèíîòåðàïèÿ:âèò Å 100 ìã 3 ð/ñóò ïåðîðàëüíî(êàæåòñÿ-ìíîãî,íî áèîäîñòóïíîñòü ó íåãî íèçêàÿ),íèêîòèíîâàÿ êèñëîòà-äî ðîçîâîé êîæè èëè íåçíà÷èòåëüíîãî ñíèæåíèÿ ÀÄ(íåäîëãî,1-2 äíÿ).5.Òî,÷òî íóæíî âñåì áåðåìåííûì-êàëüöèÿ ãëþêîíàò 0,5 ã 3 ð/ñóò ïåðîðàëüíî,êàëèÿ éîäèä 50 ìêã 1 ð/ñóò ïåðîðàëüíî.6.Ýíäîíàçàëüíûé ýëåêòðîôîðåç âèò Â1(3-4 äíÿ).7.Äèìåäðîë 1% 1,0 â/ì íà íî÷ü.....ÂѨ!Êàê âèäèòå,íîâîãî íè÷åãî,íî âåäü ðàáîòàåò!Êîíå÷íî,æàëîáû íà áîëüøîå êîëè÷åñòâî ïðåïàðàòîâ âñòðå÷àþòñÿ,íî ýòî-ìåëî÷è â ñðàâíåíèè ñ óãðîçîé 5-ãî âûêèäûøà(áûëè òàêèå áîëüíûå,íî áåç àíòèáèîòèêà ýôôåêòà íå áûëî,ê ñîæàëåíèþ...âñå áîëüøå ñêëîíÿþñü ê ìûñëè:ïðèâû÷íûé âûêèäûø=õðîíè÷åñêàÿ èíôåêöèÿ...èëè êîíòèíãåíò òàêîé?)
P.S.Áóäó áëàãîäàðåí çà Âàøè îòçûâû ïî ñõåìå ëå÷åíèÿ óãðîçû.
Ñ óâàæåíèåì,Max Melker

Êîììåíòàðèè ê ñîîáùåíèþ:
yananshs íå îäîáðèë(à):
Îòâåòèòü ñ öèòèðîâàíèåì
  #6  
Ñòàðûé 14.08.2003, 11:31
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,313
Ïîáëàãîäàðèëè 33,197 ðàç(à) çà 31,547 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìûé Ìàêñ!
Íè÷åãî ïóòíîãî ïî ïîâîäó Âàøåé ñõåìû ñêàçàòü íå ìîãó, à âîò ïî ïîâîäó àíòèáèîòèêîâ - ñëåäóþùåå:
ýðèòðîìèöèí òàêæå âñàñûâàåòñÿ ïëîõîâàòî (äî 40%): ðåêîìåíäóåìûå ïðîèçâîäèòåëåì (ABBOTT) äîçû äëÿ âçðîñëûõ: 1-2 ã â ñóòêè (ìàêñ. 4 ã): íàïð. 0,5õ3 èëè 1,0õ2. Äóìàþ, ÷òî êà÷åñòâî ïðèìåíÿåìîãî Âàìè ýðèòðîìèöèíà âñå æå ïîíèæå Àááîòîâñêîãî.
Àìîêñèöèëëèí ÿâëÿåòñÿ ïðåïàðàòîì âûáîðà äëÿ ëå÷åíèÿ õëàìèäèîçà áåðåìåííûõ:
Arch Fam Med. 1997 Nov-Dec;6(6):551-5. A decision analysis to guide antibiotic selection for Chlamydia infection during pregnancy.
Hueston WJ, Lenhart JG.
Eau Claire Family Medicine, Department of Family Medicine, University of Wisconsin-Madison Medical School, USA.
Íà îñíîâàíèè ðåòðî-àíàëèçà äåëàåòñÿ çàêëþ÷åíèå, ÷òî øèðîêî ðåêîìåíäóåìîå ñî÷åòàíèå ýðèòðîìèöèí+àìîêñèöèëëèí ÿâëÿåòñÿ äîðîãèì è íåñåò áîëüøóþ ÷àñòîòó ðåöèäèâîâ/íåóäà÷ , â òî âðåìÿ êàê amoxicillin, 500 mg 3 times a day for 7 days, followed by a single 1-g dose of azithromycin íàèáîëåå ýêîíîìè÷íûì è óñïåøíûì. Ýòî ïî ïîâîäó Âàøåé ôðàçû "àìîêñèöèëëèí åù¸ êàê-òî ìîæíî îïðàâäàòü(õîòÿ ÿ ëè÷íî íå âèæó åãî ïðåèìóùåñòâ ïåðåä ýðèòðîìèöèíîì"
Êëèíäàìèöèí îòíîñèòñÿ ê ãðóïïå B ïðåïàðàòîâ ïðè áåðåìåííîñòè: îòñóòñòâèå ôåòîòîêñè÷. äåéñòâèÿ íà æèâîòíûõ, îòñóòñòâèå äàííûõ ïî ôåòîòîêñè÷íîñòè ó ëþäåé.
Íàçíà÷åíèå 5 äíåâí. êóðñà êëèíäàìèöèíà â ñðîêè 12-22 íåä. áåðåìåííîñòè ó 244 æåíùèí ñ ïàòîëîã. âàãèí. ôëîðîé / áàê. âàãèíîçîì â Àíãëèè íå ñîïðîâîæäàëîñü êàêèìè ëèáî òîêñè÷åñêèìè ïðîÿâëåíèÿìè íà ïëîä, à ïîçâîëèëî â 3 ðàçà ñíèçèòü ÷àñòîòó ïîçäíåãî íåâûíàøèâàíèÿ è ïðåæäåâðåìåííûõ ðîäîâ ïî ñðàâíåíèþ ñ ïëàöåáî.
Lancet. 2003 Mar 22;361(9362):983-8.
Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial.
Ugwumadu A, Manyonda I, Reid F, Hay P.
Department of Obstetrics and Gynaecology, St George's Hospital, Blackshaw Road, SW17 0QT, London, UK.
Îòâåòèòü ñ öèòèðîâàíèåì
  #7  
Ñòàðûé 17.08.2003, 08:44
Àâàòàð äëÿ Vladlen
Vladlen Vladlen âíå ôîðóìà
Ïîñòîÿííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 25.05.2003
Ãîðîä: Israel
Ñîîáùåíèé: 413
Vladlen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVladlen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVladlen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVladlen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVladlen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVladlen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
ß áû âñå æå ïîñîâåòîâàë ïîéòè îáû÷íûì ïóòåì è äëÿ íà÷àëà ïðî÷èòàòü â ó÷åáíèêå ïî àêóøåðñòâó ãëàâó, ïîñâåùåííóþ ïðåýêëàìïñèè. Ôàéëû ïðèëàãàþòñÿ.
Îòâåòèòü ñ öèòèðîâàíèåì
  #8  
Ñòàðûé 17.08.2003, 08:46
Àâàòàð äëÿ Vladlen
Vladlen Vladlen âíå ôîðóìà
Ïîñòîÿííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 25.05.2003
Ãîðîä: Israel
Ñîîáùåíèé: 413
Vladlen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVladlen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVladlen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVladlen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVladlen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVladlen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ýòè äâà ôàéëà íåîáõîäèìî îáúåäèíèòü â îäèí (íà ôîðóìå âîçìîæíî îïóáëèêîâàíèå òîëüêî íåáîëüøèõ ôàéëîâ)
Îòâåòèòü ñ öèòèðîâàíèåì
  #9  
Ñòàðûé 26.08.2003, 17:55
Max Melker Max Melker âíå ôîðóìà Ïîë ìóæñêîé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 19.05.2003
Ñîîáùåíèé: 65
Max Melker ýòîò ó÷àñòíèê èìååò ïëîõóþ ðåïóòàöèþ íà ôîðóìå
Çäðàâñòâóéòå,Dr.Vad!Âàøè äàííûå âûãëÿäÿò âåñüìà óáåäèòåëüíî...Íî äàâàéòå ðàçáèðàòüñÿ:Êëèíäàìèöèí ÿâëÿåòñÿ ïðîèçâîäíûì ëèíêîìèöèíà,òîêñè÷åñêîå âëèÿíèå êîòîðîãî íà ïëîä íå âûçûâàåò ñîìíåíèé,à â ñïèñêå ïîáî÷íûõ ýôôåêòîâ-ëåéêîïåíèÿ,òðîìáîöèòîïåíèÿ...Ïðè áåðåìåííîñòè ëèíêîìèöèí ïðîòèâîïîêàçàí...Íåóæåëè êëèíäàìèöèí íå èìååò ãðåøêîâ?À àìîêñèöèëëèí ÿ ïðèìåíÿë,íî ,ê ñîæàëåíèþ,îæèäàåìîãî ýôôåêòà òàê è íå óâèäåë.Ê ïðèìåðó,ïðè ëå÷åíèè ïèåëîíåôðèòà àìîêñèöèëëèíîì âîçíèêàåò ÷óâñòâî,êàê áóäòî êàïñóëû ïóñòû!Ïðè ïåðåõîäå íà îêñàìï ýôôåêò óäîâëåòâîðèòåëüíûé,÷òî ãîâîðèò î ÷óâñòâèòåëüíîñòè ôëîðû ê ïåíèöèëëèíîâîìó ðÿäó...Âîçìîæíî,ðåêîìåíäóåìûå äîçèðîâêè àìîêñèöèëëèíà óæå íåàêòóàëüíû?Ïðè óãðîçå àìîêñèöèëëèí äåéñòâóåò ñëàáî,à ýôôåêò çàìåäëåííûé(íå íà 2-å ñóòêè,êàê ÿ ïðèâûê )Êñòàòè,ìíå ïåðåâåëè ïðåäîñòàâëåííûå Âàìè òåêñòû,òåïåðü ñ íà÷àëüíèêàìè ñòàíó âîåâàòü,óïèðàÿ íà íåçíàíèå èìè àíãëèéñêîãî
Âîò åù¸ òåìà:Åñòü òàêîé âàðèàíò ãåñòîçà,êîãäà ìàññèâíûå îòåêè ñîïðîâîæäàþòñÿ ïðîòåèíóðèåé,íî ÀÄ îñòà¸òñÿ íîðìàëüíûì èëè ïîíèæåííûì. äàííîì ñëó÷àå íóæíî ïîäíÿòü òîíóñ ñîñóäîâ,íî,êàê íàçëî,íè÷åãî áåçîïàñíîãî äëÿ ïëîäà è óäîáíîãî â ïðèìåíåíèè ïðèäóìàòü íå ìîãó...Ãëþêîêîðòèêîèäû äåéñòâóþò ïðåêðàñíî,íî â ïëàíå äëèòåëüíîãî ïðèìåíåíèÿ íåñêîëüêî ïðîáëåìàòè÷íû,êàëüöèé ïåðîðàëüíî âîîáùå ÀÄ íå ïîâûøàåò....À âåäü íóæåí ïðåïàðàò áåç êàðäèîòîíè÷åñêîãî ýôôåêòà!Ìîæåò,ó Âàñ åñòü îïûò òàêîãî ðîäà?
Ñ óâàæåíèåì,Max Melker
P.S.Ïîñò ñ çàäåðæêîé-äî èíòåðíåòà ðåäêî äîáèðàþñü
Îòâåòèòü ñ öèòèðîâàíèåì
  #10  
Ñòàðûé 26.08.2003, 18:02
Max Melker Max Melker âíå ôîðóìà Ïîë ìóæñêîé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 19.05.2003
Ñîîáùåíèé: 65
Max Melker ýòîò ó÷àñòíèê èìååò ïëîõóþ ðåïóòàöèþ íà ôîðóìå
Çäðàâñòâóéòå,Vladlen!Âûó÷ó àíãëèéñêèé,îáñóäèì Âàø gabbe íà ÿçûêå Øåêñïèðà
Ñ óâàæåíèåì,Max Melker
Îòâåòèòü ñ öèòèðîâàíèåì
  #11  
Ñòàðûé 31.08.2003, 19:31
Àâàòàð äëÿ Vladlen
Vladlen Vladlen âíå ôîðóìà
Ïîñòîÿííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 25.05.2003
Ãîðîä: Israel
Ñîîáùåíèé: 413
Vladlen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVladlen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVladlen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVladlen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVladlen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVladlen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìûé Ìàêñ.
ß âàì ïðåäëàãàþ íå îáñóæäàòü "gabbe", à ïðåæäå ÷åì "áîðîòüñÿ ñ ãåñòîçîì" âûÿñíèòü, ÷òî æå ýòî òàêîå. Ïîâåðüòå, âû áóäèòå ïðèÿòíî óäèâëåíû.

Êîììåíòàðèè ê ñîîáùåíèþ:
yananshs îäîáðèë(à):
Îòâåòèòü ñ öèòèðîâàíèåì
  #12  
Ñòàðûé 12.09.2003, 11:34
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,313
Ïîáëàãîäàðèëè 33,197 ðàç(à) çà 31,547 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìûé Ìàêñ!
Ìîæåò òàê ñòàòüñÿ, ÷òî êàïñóëû ñ àìîêñèöèëëèíîì äåéñòâèòåëüíî ïóñòû èëè àìîêñèöèëëèí â íèõ áëèçîê ïî ôîðìóëå ê àìïèöèëëèíó (ôèðìà-ïðîèçâîäèòåëü-òî êòî?): àìîêñèöèëëèí ÿâëÿåòñÿ ëèøü óëó÷øåííîé ôîðìîé àìïèöèëëèíà ïî ôàðìàêîïîêàçàòåëÿì - îí âñàñûâàåòñÿ íà 70-90%, â òî âðåìÿ êàê àìïèöèëëèí íà 40% íàòîùàê, à ïîñëå åäû ëèøü íà 20%.
Îòâåòèòü ñ öèòèðîâàíèåì
  #13  
Ñòàðûé 12.09.2003, 11:52
Max Melker Max Melker âíå ôîðóìà Ïîë ìóæñêîé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 19.05.2003
Ñîîáùåíèé: 65
Max Melker ýòîò ó÷àñòíèê èìååò ïëîõóþ ðåïóòàöèþ íà ôîðóìå
Çäðàâñòâóéòå,Vladlen!ß ïðî÷èòàë ïðåäîñòàâëåííûé Âàìè òåêñò(ïåðåâîä÷èêà íàø¸ë),è,÷åñòíî ãîâîðÿ,íå ïîíÿë,ïî÷åìó Âû ñ÷èòàåòå ïðåäîñòàâëåííóþ â í¸ì èíôîðìàöèþ íîâîé è óíèêàëüíîé..Òîñêëèâîå ñåòîâàíèå íà îòñóòñòâèå ýôôåêòà îò ïðîâîäèìîãî ëå÷åíèÿ ãåñòîçà âïîëíå ìîæíî ïðî÷èòàòü è íà ðóññêîì Ïðè ýòîì ÿ íå ñ÷èòàþ àâòîðà íåêîìïåòåíòíûì â äàííîì âîïðîñå(ïðîáëåìà äåéñòâèòåëüíî èññëåäîâàíà ãëóáîêî),íî ïî÷åìó äî ñèõ ïîð íåò ñêîëüêî-íèáóäü ñâÿçíîãî îáúÿñíåíèÿ ïàòîãåíåçà ãåñòîçîâ?Èëè ýòèîëîãèè?(óòâåðæäåíèÿ òèïà "ýòèîëîãè÷åñêèì ôàêòîðîì ÿâëÿåòñÿ áåðåìåííîñòü" íåëüçÿ ïðèíèìàòü âñåðü¸ç)À ìåòîäèêè ëå÷åíèÿ ,èçëîæåííûå â äàííîì òðóäå,áîëüøå ïîõîäÿò íà ïðåäîïåðàöèîííóþ ïîäãîòîâêó,÷åì íà ïîïûòêó êóïèðîâàòü ïàòîëîãè÷åñêèé ïðîöåññ...Òî åñòü ïîçèöèÿ àâòîðà ïîâòîðÿåò îáùåïðèíÿòóþ:"ãåñòîç íåèçëå÷èì!"À ÿ ëè÷íî íàáëþäàë ñëó÷àè óñïåøíîãî ëå÷åíèÿ... ëþáîì ñëó÷àå,ñïàñèáî çà ó÷àñòèå â ìî¸ì îáðàçîâàíèè


Ñ óâàæåíèåì,Max Melker
Îòâåòèòü ñ öèòèðîâàíèåì
  #14  
Ñòàðûé 12.09.2003, 12:02
Max Melker Max Melker âíå ôîðóìà Ïîë ìóæñêîé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 19.05.2003
Ñîîáùåíèé: 65
Max Melker ýòîò ó÷àñòíèê èìååò ïëîõóþ ðåïóòàöèþ íà ôîðóìå
Çäðàâñòâóéòå,Dr.Vad!Ôèðìó-ïðîèçâîäèòåëÿ àìîêñèöèëëèíà íå ïîìíþ(äàâíî äåëî-òî áûëî),íî ÿ ïîëüçîâàëñÿ òàêæå òàáëåòèðîâàííîé ôîðìîé ñ òåì æå óñïåõîì...À ýðèòðîìèöèí èñïîëüçóþ ðîññèéñêèé è íè÷åãî ïëîõîãî â ýòîì íå âèæó Òàê êàê íàñ÷¸ò ïàðî÷êè ëèíêîìèöèí-êëèíäàìèöèí(áëèçêîå ðîäñòâî ñîìíåíèé íå âûçûâàåò?),õîòåëîñü áû çíàòü Âàøå ìíåíèå...

Ñ óâàæåíèåì,Max Melker
Îòâåòèòü ñ öèòèðîâàíèåì
  #15  
Ñòàðûé 12.09.2003, 12:03
Àâàòàð äëÿ Vladlen
Vladlen Vladlen âíå ôîðóìà
Ïîñòîÿííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 25.05.2003
Ãîðîä: Israel
Ñîîáùåíèé: 413
Vladlen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVladlen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVladlen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVladlen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVladlen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVladlen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ïðåäîñòàâëåííûé òåêñò - îòðûâîê èç ó÷åáíèêà, ïîýòîìó ýòî íå "íîâàÿ è óíèêàëüíàÿ" èíôîðìàöèÿ, à îáùåïðèíÿòûé ïîäõîä.
Ãîâîðÿ î ëå÷åíèè, ñëåäóåò ïîìíèòü î åãî öåíå, íàïðèìåð, î ðèñêå äëÿ ðåáåíêà. Íà ñåãîäíÿøíèé äåíü ðîäîðàçðåøåíèå íà ñðîêå, ñêàæåì, áîëüøå 30 íåäåëü ïîñëå íåêîòîðîé ïîäãîòîâêè áåðåìåííîé ( ñòåðîèäû, àíòèáèîòèêè) íå ïðåäñòàâëÿò áîëüøåé îïàñíîñòè äëÿ æèçíè è äàëüíåéøåãî ðàçâèòèÿ ðåáåíêà.
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 23:49.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.